🐦 推特Wall St EngineCodex · 实盘不做把握 6/10
北京时间·🕒 发布 18:07:01时区推断·⟳ 抓取 18:07:01·⚡ 决策 07-21 18:09:06 +2m05s·98.1 天前
丹纳赫二季度业绩小幅超预期并小幅上调全年调整后EPS指引
丹纳赫（DHR.US）二季度收入63亿美元略高于预期62.7亿美元，调整后EPS 1.94美元高于预期1.84美元，事件本身偏正面。
📄 原文Wall St Engine@wallstengine↗ 原文
DANAHER $DHR Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $6.3B (Est. $6.27B) 🟡; +5.5% YoY 🔹 Adj. EPS: $1.94 (Est. $1.84) 🟢; +8…
不做 丹纳赫（DHR.US）
不做：同一具体财报催化近6小时内已被处理，且本次beat和全年指引上调幅度温和，盘前价格反而下跌，缺少可执行的正期望追多edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-21 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 丹纳赫（DHR.US）二季度收入63亿美元略高于预期62.7亿美元，调整后EPS 1.94美元高于预期1.84美元，事件本身偏正面。
- 全年调整后EPS指引8.45-8.60美元相对市场预期8.50美元仅小幅偏中性，上调主要来自Masimo收购提前完成，缺少足以驱动1423亿美元市值短线重定价的超预期增量。
- 行情显示DHR.US在消息时点报价201.11美元、较前收跌1.33%，市场没有用盘前价格确认强正向重定价。
主要风险
- 财报类事件默认预期充分，当前收入与全年EPS指引相对一致预期的正向差距较小，容易被解读为利好有限。
- 近20日DHR.US已上涨13.75%，且本条同一具体催化近6小时内已被系统处理过，重复推卡和追财报的性价比都不高。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 900 字
DANAHER $DHR Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $6.3B (Est. $6.27B) 🟡; +5.5% YoY
🔹 Adj. EPS: $1.94 (Est. $1.84) 🟢; +8.0% YoY
🔹 FCF: $1.3B; +~15.5% YoY
Raises FY26 Guide:
🔹 Adj. EPS: $8.45-$8.60 (Est. $8.5) 🟡
🔹 Core Revenue Growth: +3.0%-+4.0%
Segment Revenue:
🔹 Biotechnology: +4.0% YoY
🔹 Life Sciences: +5.5% YoY
🔹 Diagnostics: +7.0% YoY
Business Highlights:
🔹 Pending Acquisition: Leica Biosystems to acquire StatLab
🔹 Masimo Acquisition: Completed earlier-than-anticipated, enabling increased FY26 Adj. EPS guidance
Comments:
🔸 “We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth.”
🔸 “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.”
🔹 Revenue: $6.3B (Est. $6.27B) 🟡; +5.5% YoY
🔹 Adj. EPS: $1.94 (Est. $1.84) 🟢; +8.0% YoY
🔹 FCF: $1.3B; +~15.5% YoY
Raises FY26 Guide:
🔹 Adj. EPS: $8.45-$8.60 (Est. $8.5) 🟡
🔹 Core Revenue Growth: +3.0%-+4.0%
Segment Revenue:
🔹 Biotechnology: +4.0% YoY
🔹 Life Sciences: +5.5% YoY
🔹 Diagnostics: +7.0% YoY
Business Highlights:
🔹 Pending Acquisition: Leica Biosystems to acquire StatLab
🔹 Masimo Acquisition: Completed earlier-than-anticipated, enabling increased FY26 Adj. EPS guidance
Comments:
🔸 “We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth.”
🔸 “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。